Drug firm FDC launches stronger versions of Favipiravir at Rs 160 per tablet in India
The 800 mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75 percent, it added.
New Delhi: Drug firm FDC Ltd on Friday said it has launched stronger versions of its Favipiravir brands, PiFLU and Favenza, used to treat mild-to-moderate cases of COVID-19, at a price of Rs 160 per tablet in India.
These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from November 1, 2020, FDC said in a BSE filing.
The 800 mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75 percent, it added.
"After the launch of PiFLU and Favenza in August, we decided to work on reducing the dosage frequency as well as the cost, as a result of which we have introduced this variant," FDC Business Development and Commercial Excellence G M Mayank Tikkha said.
PiFLU-800 and Favenza-800 will help patients reduce the cost of therapy by 30 percentpercent, while strengthening efficacy of treatment, he added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.